Overview
Cagrilintide is a long-acting acylated analog of human amylin, a 37-amino acid peptide hormone co-secreted with insulin from pancreatic beta cells. Developed by Novo Nordisk, cagrilintide represents a novel approach to obesity pharmacotherapy by targeting the amylin receptor system, which plays a critical role in satiety signaling, gastric emptying regulation, and post-meal glucagon suppression.
The compound has generated particular excitement as part of the CagriSema combination (cagrilintide + semaglutide 2.4 mg), which achieved unprecedented weight loss in clinical trials—up to 15.6% in Phase 2 and potentially exceeding 25% in Phase 3 studies. This combination targets two complementary anorectic pathways: GLP-1 receptor agonism (semaglutide) and amylin receptor agonism (cagrilintide).
Amylin biology has been validated in obesity treatment since the approval of pramlintide (Symlin) for diabetes in 2005, but pramlintide's short half-life requiring multiple daily injections limited its practical use. Cagrilintide overcomes this limitation through acylation technology (similar to semaglutide's albumin-binding modification) that extends the half-life to support once-weekly dosing.
Phase 3 clinical trials for CagriSema are ongoing, with results expected to potentially establish a new standard of care in pharmaceutical obesity treatment. This guide reviews the amylin pathway, clinical data, and the significance of cagrilintide in the evolving weight management landscape.
Quick facts
- Mechanism
- Long-acting amylin analog for appetite and metabolic control
- Primary use
- Obesity & Weight Management
- Evidence
- strong
- FDA
- Not approved
- Route
- Subcutaneous injection (once weekly)
- Typical results
- 10–15% body weight loss as monotherapy; up to 25% in combination with semaglutide
Chemical information
Cagrilintide is an acylated amylin analog with a molecular mass of approximately 4,409 g/mol (C₁₉₄H₃₁₂N₅₄O₅₉S₂). It features modifications to the native human amylin sequence including amino acid substitutions for stability and an octadecanedioic acid (C18 fatty diacid) attached via a gamma-glutamic acid linker, enabling albumin binding and extended half-life.
How Cagrilintide works
Cagrilintide activates the amylin receptor complex, which consists of the calcitonin receptor (CTR) paired with receptor activity-modifying proteins (RAMPs), particularly RAMP1, RAMP2, and RAMP3. These receptors are densely expressed in the area postrema and nucleus of the solitary tract in the brainstem—regions that integrate peripheral metabolic signals with central appetite control circuits.
Upon amylin receptor activation, cagrilintide triggers neuronal signaling cascades that reduce food intake through multiple complementary mechanisms. It enhances meal-related satiety by slowing gastric emptying, suppresses post-prandial glucagon secretion (reducing hepatic glucose output), and activates hypothalamic neurons involved in energy homeostasis. The anorectic effect is particularly pronounced for hedonic (pleasure-driven) eating rather than homeostatic hunger.
The acylation of cagrilintide with a C18 fatty diacid enables non-covalent binding to serum albumin, dramatically extending its half-life from minutes (native amylin) to approximately 7 days. This pharmacokinetic modification allows once-weekly subcutaneous administration while maintaining steady-state receptor engagement throughout the dosing interval.
The synergy with GLP-1 receptor agonists like semaglutide is mechanistically well-founded: amylin and GLP-1 activate distinct but overlapping neural circuits in the brainstem and hypothalamus. Preclinical data suggest that combined amylin + GLP-1 agonism produces greater suppression of food intake and body weight than either agent alone, with the amylin pathway providing additional benefits on food reward processing and meal size reduction.
- Amylin receptor agonism: Activates CTR/RAMP complexes in brainstem appetite centers
- Gastric emptying delay: Slows nutrient absorption, prolonging satiety signals
- Glucagon suppression: Reduces post-meal hepatic glucose output
- Hedonic appetite reduction: Diminishes reward-driven eating through central circuits
- Hypothalamic integration: Modulates energy balance set-point through POMC/AgRP neurons
- GLP-1 synergy: Complementary pathway activation amplifies weight loss when combined with semaglutide
Pharmacokinetics
Pharmacokinetic data from Phase 1–3 clinical trials in adults with obesity.
| Parameter | Value | Significance |
|---|---|---|
| Bioavailability (SC) | ~80% | High absorption supports reliable dosing |
| Half-life | ~160 hours (6.7 days) | Supports once-weekly dosing |
| Tmax | 24–72 hours | Gradual absorption from SC depot |
| Protein binding | >99% (albumin) | Acylation technology enables extended duration |
| Steady state | 3–4 weeks | Full effects after initial dose escalation |
| Metabolism | Proteolytic degradation | No significant hepatic CYP interactions |
Dosing & administration
In clinical trials, cagrilintide is titrated from 0.25 mg weekly to a maintenance dose of 2.4 mg weekly over approximately 16 weeks. The dose escalation schedule (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg) is designed to minimize gastrointestinal side effects, particularly nausea, which typically diminishes with continued use.
In the CagriSema combination, cagrilintide 2.4 mg is co-administered with semaglutide 2.4 mg as separate once-weekly injections (a fixed-dose combination pen is in development). Both agents follow parallel dose escalation schedules.
Cagrilintide is not yet commercially available as a monotherapy. Its primary development pathway is as part of CagriSema. Dosing recommendations will be established upon regulatory approval.
Important: These dosing ranges are not FDA-approved. Any use should be under qualified medical supervision.
Side effects & safety
Cagrilintide has demonstrated an acceptable safety profile in Phase 2 and Phase 3 trials. The most common adverse events are gastrointestinal (nausea, vomiting, diarrhea), which are dose-related and typically diminish with continued treatment and proper dose escalation. The combination with semaglutide did not show unexpected safety signals beyond what was anticipated from either mechanism.
Common
- • Nausea (20–30%, typically dose-related and transient)
- • Vomiting (8–12%)
- • Diarrhea
- • Constipation
- • Injection site reactions
- • Decreased appetite (therapeutic effect)
Serious / potential risks
- • Severe nausea/vomiting requiring dose adjustment
- • Potential pancreatitis (class monitoring, not confirmed)
- • Theoretical thyroid C-cell concerns (amylin class)
- • Gallbladder events with rapid weight loss
- • Hypoglycemia risk when combined with insulin
Drug interactions
Drug interaction data is available from clinical trial programs.
| Medication | Interaction | Recommendation |
|---|---|---|
| Insulin | Additive hypoglycemia risk; both lower blood glucose | Reduce insulin dose by 20–30% when initiating; monitor closely |
| Sulfonylureas | Increased hypoglycemia risk | Consider dose reduction; frequent glucose monitoring |
| Oral medications | Delayed gastric emptying may affect absorption kinetics | Take critical oral medications 1 hour before cagrilintide |
| Semaglutide (CagriSema) | Intentional combination; complementary mechanisms | Used together in clinical development; additive GI effects |
| Acetaminophen / NSAIDs | Delayed absorption due to gastric emptying effects | Clinical significance likely minor; monitor analgesic onset |
Storage & handling
Pre-filled Pen (Expected)
- • Store at 2–8°C (36–46°F) before first use
- • May be kept at room temperature for up to 21 days after first use
- • Protect from direct sunlight and freezing
- • Discard pen after 21 days at room temperature
Combination Pen (CagriSema - In Development)
- • Fixed-dose combination pen format in development
- • Expected storage requirements similar to semaglutide pens
- • Do not freeze; store refrigerated until first use
- • Attach new needle for each injection
Cost & availability
| Source | Cost | Notes |
|---|---|---|
| Clinical trials | Not yet commercially available | Phase 3 trials ongoing; expected FDA submission 2024–2025 |
| Projected pricing (CagriSema) | $1,000–$1,500/month (estimated) | Expected premium pricing over semaglutide alone |
| Comparison: Wegovy | $1,349/month (list price) | CagriSema expected to command premium for superior efficacy |
The bottom line
Cagrilintide is a metabolic compound with research interest in weight loss, amylin analog, appetite control, metabolic syndrome. While preclinical evidence is encouraging, it remains investigational and is not FDA-approved. Any use should be under qualified medical supervision.
Best for
- • Researchers studying metabolic regulation and energy homeostasis
- • Individuals interested in weight loss under medical guidance
Not for
- • Self-administration without medical supervision
- • Pregnant or breastfeeding individuals
- • Individuals with contraindicated conditions
Related compounds
Frequently asked questions
References
- [1] Lau DCW, Erichsen L, Francisco-Ziller N, et al.. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet (2021). doi: 10.1016/S0140-6736(21)01751-7 PMID: 34798060
- [2] Enebo LB, Berthelsen KK, Kankam M, et al.. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet (2021). doi: 10.1016/S0140-6736(21)00845-X PMID: 34358470
- [3] Hay DL, Chen S, Lutz TA, et al.. Amylin: pharmacology, physiology, and clinical potential. Pharmacol Rev (2015). doi: 10.1124/pr.115.010629 PMID: 26598340
- [4] Lutz TA.. Control of energy homeostasis by amylin. Cell Mol Life Sci (2012). doi: 10.1007/s00018-011-0905-1 PMID: 22218526
- [5] Frias JP, Deenadayalan S, Erichsen L, et al.. Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Lancet (2023). doi: 10.1016/S0140-6736(23)01163-7 PMID: 37524095